FDA clears myotrophin early-access program for patients with ALS

被引：0
|
作者：
不详
机构：
来源：
DRUG NEWS & PERSPECTIVES | 1996年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：370 / 370
页数：1
相关论文
共 50 条
  • [41] Immunocompromised patients with resistant HSV infections: the international early access program of pritelivir
    Avery, R. K.
    Dickter, J.
    Polak, T.
    Truebel, H.
    Sumner, M.
    Birkmann, A.
    Lee, Y. J.
    Neofytos, D.
    SWISS MEDICAL WEEKLY, 2022, 152 : 21S - 21S
  • [42] CABAZITAXEL PLUS PREDNISONE (CBZP) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL (D): EFFICACY AND SAFETY RESULTS FROM EARLY-ACCESS PROGRAM (EAP) SINGLE SITE EXPERIENCE
    Rescigno, P.
    D'Aniello, C.
    Federico, P.
    Puglia, L.
    Petremolo, A.
    Cavaliere, C.
    Buonerba, C.
    De Placido, S.
    Di Lorenzo, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 316 - 317
  • [43] 360 VIEW OF THE FRENCH EARLY ACCESS PROGRAM
    Cardon, S. C.
    Kachaner, I
    Bougeois, M.
    Grand, H.
    Cogez, F.
    VALUE IN HEALTH, 2020, 23 : S657 - S657
  • [44] Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
    Speers, Marjorie A.
    PHARMACEUTICAL MEDICINE, 2019, 33 (02) : 89 - 98
  • [45] Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
    Marjorie A. Speers
    Pharmaceutical Medicine, 2019, 33 : 89 - 98
  • [46] Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)
    Chiattone, Carlos Sergio
    Hamerschlak, Nelson
    Fogliatto, Laura
    Scheinberg, Phillip
    Bigni, Ricardo
    Rodrigues, Celso
    Garicochea, Bernardo
    Pimenta, Alex
    Boechat, Tiago Oliveira
    Musacchio, Juliane
    Bortolini, Jaisson
    Goncalves, Iara Zapparoli
    Matias Vieira, Garles Miller
    Buccheri, Valeria
    Santos, Telma
    Grings, Mariana
    Parisi, Lori
    Barreyro, Paula
    BLOOD, 2018, 132
  • [47] Hypermetabolism in ALS patients: an early and persistent phenomenon
    Bouteloup, C.
    Desport, J. -C.
    Clavelou, P.
    Guy, N.
    Derumeaux-Burel, H.
    Ferrier, A.
    Couratier, P.
    JOURNAL OF NEUROLOGY, 2009, 256 (08) : 1236 - 1242
  • [48] Assessing patients' access to tetrabenazine (xenazine) after FDA approval
    Palao, A. M.
    Mostile, G.
    Hunter, C. B.
    Jankovic, J.
    MOVEMENT DISORDERS, 2010, 25 (07) : S275 - S275
  • [49] Hypermetabolism in ALS patients: an early and persistent phenomenon
    C. Bouteloup
    J.-C. Desport
    P. Clavelou
    N. Guy
    H. Derumeaux-Burel
    A. Ferrier
    P. Couratier
    Journal of Neurology, 2009, 256 : 1236 - 1242
  • [50] BLR update: Approvals for photodynamic therapy, bone breakdown activity - FDA clears treatment for early lung cancer, test for osteoporosis
    不详
    BIOTECHNOLOGY LAW REPORT, 1998, 17 (02): : 278 - 279
12345